Patent 6913768 Issued on July 5, 2005. Estimated Expiration Date: January 29, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
Other References
US 6,034,101, 3/2000, Gupta et al. (withdrawn)
Walia et al., Preliminary Evaluation of an Aqueous Wax, Emulsion for Controlled-Release Coating, Pharm. Dev. Tech., vol. 3, No. 1, pp. 103-113 (1998).
Banker et al., Modern Pharmaceutics, eds., Marcel Dekker, Inc., New York, p. 350 (1996).
Gazzaniga et al., “Time-Dependent oral Delivery Systems for Colon Targeting,” S.T.P. Pharma Sciences 5(1):83-88 (1995).
Walia et al., “Preliminary Evaluation of An Aqueous Wax Emulsion for Controlled-Release Coating,” Pharmaceutical Development and Technology, 3(1):103-113 (1998).
Gazzaniga et al., “Oral Chronotopic Drug Delivery Systems: Achievement of Time And/Or Site Specificity,” Eur. J. Pharm. Biopharm, 40(4):246-250 (1994).
Pozzi et al., “The Time Clock System: A New Oral Dosage form for Fast and Complete release od Drug After a Predetermined Lag Time,” Journal of Controlled Release, 31:99-108 (1994).
Wilding et al., “Gastrointestinal Transit and Systemic Absorption of Captopril From A Pulsed-Release Formulation,” Pharmaceutical Research, 9 (5):654-657(1992).
Xin Xu et al., “Programmable Drug Delivery From An Erodible Association Polymer System,” Pharmaceutical Research, 10(8):1144-1152 (1993).
Conte et al., “Press-Coated tablets for Time-Programmed Release of Drugs,” Biomaterials, 14(13):1017-1023 (1993).
R. Gurny et al., Pulsatile Drug Delivery Current Applications and Future Trends, pp. 112-134, (1993).
Adderall, Package Insert, May 1996, Physicians' Desk Reference 1997.
K. S. Patrick et al., “Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit . . . ” Human Psychopharmacology, vol. 12, pp. 527-546, 1997.
Lisa H. Brauer et al., “Acute Tolerance to Subjective but Not Cardiovascular Effects of d-Amphetamine in Normal, Healthy Men,” Journal of Clinical Psychopharmacology, vol. 16, No. 1, pp. 72-76, 1996.
William P. Melega et al., “Pharmacokinetic and Pharmacodynamic Analysis of the Actions of D-Amphetamine and D-Methamphetamine on the Dopamine Terminal,” The Journal of Pharmacology and Experimental Therapeutics, vol., 274, No. 1, pp, 90-96, 1995.
Peter Clausing et al., “Amphetamine Levels in Brain Microdialysate, Caudate/Putamen, Substantia Nigra and Plasma After Dosage That Produces Either Behavioral . . . ” The Journal of Pharmacology and Experimental Therapeutics, vol. 274, No. 2, pp. 614-621, 1995.
S.B. Sparber et al., “Amphetamine Cumulation and Tolerance Development: Concurrent and Opposing Phenomena,” Pharmacology Biochemistry & Behavior, vol. 20, pp, 415-424, 1984.
Burt Angrist et al., “Early Pharmacokinetics and Clinical Effects of Oral D-Amphetamine in Normal Subjects,” Biol Psychiatry, vol. 22, pp. 1357-1368, 1987..
Gerald L. Brown et al., Plasma Levels of d-Amphetamine in Hyperactive Children, PSYCHOPHARMACOLOGY, vol. 62, pp. 133-140, 1979.
Suk Han Wan et al., “Kinetics, Salivary Excretion of Amphetamine Isomers, and Effect of Urinary pH,” Clin. Pharmacol. Ther., pp. 585-590, May 1978.
Gerald L. Brown et al., “Plasma d-Amphetamine Absorption and Elimination in Hyperactive Children,” Psychopharmacology Bulletin, vol. 14, No. 3, pp. 33-35, 1978.
Excerpts from Feb. 2, 2005 Deposition of Beth A. Burnside in Shire Laboratories Inc v Barr Laboratories, Inc., 03-CV-1219 and 03-CV-6632 (PKC), SDNY, pp. 1, 2 and 143-150.
Excerpts from Feb. 3, 2005 Deposition of Beth A Burnside in Shire Laboratories Inc v Impax Laboratories Inc, 03-CV-1164 (GMS), D.Delaware, pp. 1-5 and 190-197.
January 29, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
